Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorDafni, U.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorGogas, H.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorMoulopoulos, L. A.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorManiadakis, N.en
dc.contributor.authorSiafaka, V.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorTsavdaridis, D.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorRazis, E.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorDimopoulos, M. A.en
dc.date.accessioned2015-11-24T19:00:11Z
dc.date.available2015-11-24T19:00:11Z
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19493
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/pathologyen
dc.subjectCarboplatin/administration & dosageen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosageen
dc.subjectSurvival Analysisen
dc.subjectTreatment Outcomeen
dc.titlePaclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Groupen
heal.abstractBACKGROUND: To compare survival between patients with advanced breast cancer (ABC) treated with epirubicin/paclitaxel (Taxol) or paclitaxel/carboplatin (Cp) chemotherapy. PATIENTS AND METHODS: From January 1999 to April 2002, 327 eligible patients with ABC were randomized to receive either paclitaxel 175 mg/m(2) in a 3-h infusion followed by epirubicin (EPI) 80 mg/m(2) (group A) or paclitaxel, as in group A, followed by Cp at an AUC of 6 mg x min/ml (group B) every 3 weeks for six cycles. RESULTS: After a median follow-up of 23.5 months, median survival was not significantly different between the two groups (22.4 months versus 27.8 months, P=0.25), whereas median time to treatment failure was significantly longer in patients treated with paclitaxel/Cp (8.1 months in group A versus 10.8 months in group B, P=0.04). Both regimens were well tolerated. In total, 39 patients (24%) in group A and 46 (29%) in group B suffered at least one severe side-effect. Quality-of-life assessment and cost analysis did not reveal any significant differences between the two groups. CONCLUSION: Our study suggests that the paclitaxel/Cp combination is an effective therapeutic alternative for patients with ABC in which anthracycline administration has the potential of being harmful.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1093/annonc/mdh395-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15367413-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/15/10/1517.full.pdf-
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2004-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ